clinical trial · NCT05164471
Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
Hemophilia Bverbrinacogene setparvovec
brief summary
Study of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a future Phase 3 study.
started
Dec 6, 2021
primary completion
May 31, 2023
completion
May 31, 2023
last updated
Jul 20, 2023
official title
A Dose Confirmation Study of FLT180a (Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene) in Adult Subjects With Hemophilia B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol